Healthcare · Risk & Compliance
Governed AI-Native Fraud and Risk Triage for Biotechnology
We design, build, and run AI-native fraud and risk triage for biotech founders, clinical operations teams, business development leaders, and scientific program managers. This page describes the engagement: scope, pricing, timeline, controls, and the KPIs we commit to.
Early access: we work with a small first cohort. Engagements are scoped, priced, and shipped end-to-end by our team — not referred to third parties.
In one sentence
AI-native fraud and risk triage for biotechnology is a phased engagement (Discovery 2 weeks → Build 9 weeks → Run continuous (integration-heavy)) that ships a production workflow on top of ELN and LIMS, moves false positive rate by −86% against the biotechnology baseline, and is operated under risk & compliance governance from day one.
Key facts
- Industry
- Biotechnology
- Use case
- Fraud and Risk Triage
- Intent cluster
- Risk & Compliance
- Primary KPI
- false positive rate, investigation time, loss avoided, and reviewer throughput
- Top benchmark
- Time-to-attestation: 21 days → 3 days (−86%)
- Systems integrated
- ELN, LIMS, clinical trial systems
- Buyer
- biotech founders, clinical operations teams, business development leaders, and scientific program managers
- Risk lens
- scientific validity, IP protection, trial documentation, privacy, and investor communication accuracy
- Engagement timeline
- Discovery 2 weeks → Build 9 weeks → Run continuous (integration-heavy)
- Team size
- 1 senior delivery + 1 part-time domain SME
- Discovery price
- $8k · 2-3 week sprint
- Build price
- $30k–$40k · 8-12 weeks
Primary outcome
prioritize risky activity before it becomes expensive
What we ship
risk triage assistant, case summaries, investigation workflows, and reviewer QA
KPIs we report on
false positive rate, investigation time, loss avoided, and reviewer throughput
Why Biotechnology teams hire us for this
Three forces compound on biotechnology teams trying to scale fraud and risk triage: rising operator cost, rising volume, and rising quality expectations. Headcount-led growth is no longer mathematically viable; AI-native delivery is the only path that lets quality go up *while* unit cost goes down — provided the operating discipline is in place from day one.
Biotechnology compliance teams routinely report that reviewing AI-generated outputs is faster than reviewing human-generated outputs — as long as the AI system surfaces the supporting evidence at the same time. That is a design choice, not a model capability.
Industry context: Mid-market and enterprise operators face the same fundamental tradeoff: AI must compress operational cycle time while remaining auditable and integrable with existing systems of record.
Benchmarks we hit
Reference benchmarks from production deployments of fraud and risk triage in biotechnology-comparable contexts. Sources noted per row. Your actuals are measured against the baseline captured in Discovery.
| Metric | Industry baseline | AI-native typical | Delta |
|---|---|---|---|
Time-to-attestation Quarterly attestation packs assembled from audit log; reviewer signs off in hours | 21 days | 3 days | −86% |
Loss avoided / quarter (vs no AI) Conservative estimate; actuals depend on fraud volume + ticket size | $0 (no AI lift) | $280k median | Net positive |
Review backlog clearance False-positive triage automated; reviewers see only the cases that need them | 14 days | 1.8 days | −87% |
Benchmarks are reference values from comparable engagements and authoritative sector benchmarks. Your engagement's baseline is captured during Discovery and actuals are reported weekly during Run against that baseline.
How we operate the workflow
The hardest part of AI-native fraud and risk triage is not the LLM call — it is mapping the current process, finding where judgment is required, identifying which decisions need evidence, and separating high-confidence automation from cases that need human approval. We dedicate the full Discovery sprint to that mapping before any code is written.
What we build inside the workflow
The single most common mistake we see biotechnology teams make when Building fraud and risk triage is over-investing in prompt quality and under-investing in evaluation infrastructure. We invert that ratio: prompts are iterated weekly against a fixed labelled test set, and the labelled test set is treated as the most valuable artefact of the engagement. Without it, every change is a guess.
Reference architecture
4-layer AI-native workflow for risk & compliance
Source intake → AI orchestration → Action → Human review & quality.See the full architecture diagram for Risk & Compliance →
AI-native vs traditional approach
How a scoped AI-native engagement compares to the traditional alternatives for fraud and risk triage in biotechnology.
| Dimension | Traditional (in-house build or BPO) | AI-native engagement (us) |
|---|---|---|
| Time to production | 6-12 months | 6-10 weeks (thin slice) |
| Pricing model | FTE hourly retainer or fixed staffing | Phased fixed-price (Discovery → Build → opt Run) |
| Audit / governance | Manual logs, periodic review | Versioned prompts, audit logs, reviewer queues, attestations |
| Operator throughput lift | 1.0× (baseline) | Net positive |
| Cost per unit | Industry baseline | AI-native engagements deliver thin-slice production in 6-8 weeks with measurable baseline-vs-actuals reporting. |
| Exit path | Multi-quarter notice + knowledge loss | Month-to-month Run, full handover plan in Build SoW |
Traditional process automation projects cost $80-200k+ with 6-12 month payback; AI-native engagements deliver thin-slice production in 6-8 weeks with measurable baseline-vs-actuals reporting.
Engagement scope & pricing
We run this as a fixed-scope engagement with a clear commercial envelope, not an open-ended retainer.
Governed engagement
Three phases, billed separately. You commit one phase at a time.
Phase 1 · Discovery
$8k
2-3 week sprint
Phase 2 · Build
$30k–$40k
8-12 weeks
Phase 3 · Run
$4k–$6k / mo
optional, quarterly attestations available
~$52k–$90k typical year 1 (~80% take the run option, regulated workflows need ongoing controls)
Controls, audit logs, reviewer queues, versioned prompts, and quarterly risk attestations.
Discovery is the only commitment to start. After Discovery, we scope Build with a fixed price. Run is opt-in, month-to-month, no lock-in.
The 4-phase delivery model
Phase 1 · Weeks 1–2
Discovery
We map the workflow, the systems, the decisions, and the baseline metrics. Output: a scoped statement of work.
Phase 2 · Weeks 2–4
Design
We design the operating model: data access, retrieval, prompts, review queues, controls, and the KPI dashboard.
Phase 3 · Weeks 4–8
Build
We ship a production thin slice on real data, with versioned prompts, evaluation harness, and human review.
Phase 4 · Weeks 8+
Run
We run the workflow with you weekly, expand into adjacent work, and report against baseline.
Interactive ROI calculator
Estimate your AI-native ROI for fraud and risk triage
Reference inputs below are typical for biotechnology teams in the risk compliance cluster. Adjust them to match your situation.
Projected
Current monthly cost
$57,000
AI-native monthly cost
$20,070
Annual savings
$443,160
65% cost reduction · ~656 operator-hours freed / month
Governance and risk controls
Governance fails in two predictable ways in biotechnology: paper controls that nobody enforces at runtime, and runtime controls that nobody can document for auditors. We build for both audiences. Every guardrail is enforced in code, and every guardrail is documented in the governance map with the line of code that implements it. The map and the code are kept in sync as part of the Run cadence.
How we report ROI
The ROI calculation we refuse to fudge on fraud and risk triage is the time-to-value curve. Most biotechnology AI projects report ROI on cherry-picked metrics at quarter-end. We report against a baseline captured in Discovery, on a fixed metric defined before Build, with the methodology documented in the Statement of Work. Boring, defensible, repeatable.
Common pitfall & mitigation
The failure mode we see most often on AI-native fraud and risk triage engagements in biotechnology contexts.
Hallucinated citations under deadline pressure
AI fabricates a regulation reference during a busy week, reviewer misses it
Citation grounding required (no citation = refuse); periodic adversarial test set with fake-citation triggers
Build internally or work with us
The strongest pattern we see in biotechnology is blended: we design and launch the first production workflow, your internal team owns data access, security review, and stakeholder alignment. Over 6-12 months, your team takes over Run while we move to the next workflow. The exit plan is part of the Statement of Work.
What to ask us before signing
- Ask for a workflow map that shows intake, retrieval, generation, review, escalation, system updates, and measurement.
- Ask for an evaluation plan using real examples from biotechnology, not only generic test prompts.
- Ask how we will move false positive rate, investigation time, loss avoided, and reviewer throughput within the first 30 to 60 days.
- Ask which parts of the process remain human-owned and why.
- Ask for our exit plan: what stays with you if the engagement ends.
Recommended first project
The best first project for AI-native fraud and risk triage in biotechnology is a contained workflow with enough volume to matter and enough structure to evaluate. Avoid the most politically sensitive process first. Avoid a workflow with no measurable baseline. Choose a process where we can ship a production-grade thin slice, prove adoption, and then extend the same architecture to neighboring work.
A practical target is a 30-day build followed by a 60-day operating period. In the first 30 days, we map the work, connect the minimum data sources, build the assistant, and create the review process. In the next 60 days, the system handles real volume, the team measures outcomes, and we improve the workflow weekly. By day 90, leadership knows whether to expand into adjacent work.
Frequently asked questions
How do you automate fraud and risk triage in biotechnology with AI?+
We map the existing fraud and risk triage workflow inside biotechnology, identify the high-volume, high-structure tasks, and build an AI agent that handles those tasks while routing low-confidence cases to a human reviewer. The build connects to your ELN, LIMS, clinical trial systems, runs against a labelled test set, and ships behind a reviewer queue before it sees production traffic. We then operate it, measure false positive rate, investigation time, loss avoided, and reviewer throughput, and improve it weekly.
What does it cost to automate fraud and risk triage for a biotechnology company?+
Three phases, billed separately. Discovery sprint: $8k (2-3 week sprint). Build engagement: $30k–$40k (8-12 weeks). Run retainer: $4k–$6k / mo (optional, quarterly attestations available). ~$52k–$90k typical year 1 (~80% take the run option, regulated workflows need ongoing controls). Controls, audit logs, reviewer queues, versioned prompts, and quarterly risk attestations.
What is the best AI agent for fraud and risk triage in biotechnology?+
There is no single "best" off-the-shelf agent for fraud and risk triage in biotechnology — the right architecture depends on your ELN setup, your data, and your risk profile. We typically combine a frontier LLM (Claude, GPT-4-class, or Gemini) with a retrieval layer over your approved sources, tool-use for ELN and LIMS integrations, and a reviewer queue. We benchmark candidate models against a labelled test set during Discovery and pick the one with the best accuracy/cost ratio for your workflow.
How long does it take to deploy AI fraud and risk triage for biotechnology?+
A thin-slice deployment in 2-3 week sprint after Discovery, with real biotechnology data and real reviewers. The full Build phase runs 8-12 weeks. By day 90, false positive rate, investigation time, loss avoided, and reviewer throughput is instrumented, the team has a baseline, and leadership has the data needed to decide on expansion into adjacent biotechnology workflows.
What do we own, and what do you own?+
We own the workflow design, the prompts, the retrieval architecture, the evaluation harness, and weekly improvement. Your biotech founders, clinical operations teams, business development leaders, and scientific program managers team owns data access, policy, exception approval, and final commercial decisions. At the end of the engagement, every prompt, eval, and config is handed over — no lock-in.
How do you handle risk and audit for AI fraud and risk triage in biotechnology?+
Every output is grounded in approved sources, every prompt is versioned, and every reviewer action is logged. We provide a control map covering scientific validity, IP protection, trial documentation, privacy, and investor communication accuracy, plus quarterly attestations on request.
Sources we reference
The following sources inform the architecture, governance, and benchmarks we apply on biotechnology engagements. Cited here so you can verify and dig deeper.
- NIH Artificial Intelligence
- Hype Cycle for Artificial Intelligence — Gartner
- MIT Sloan Management Review — AI & Business Strategy — MIT Sloan
- Model Risk Management Handbook — Federal Reserve (SR 11-7)
- Principles for the Sound Management of AI Risks — BIS Financial Stability Institute
- Google Search Central: helpful, reliable, people-first content
- Google Search Central: URL structure best practices
Concepts on this page:
AI governance·NIST AI RMF·Audit log·Grounding·Guardrails·Model cardFull glossary →Start the engagement
Book a discovery call for Biotechnology
Tell us about your workflow, the systems involved, and the KPI you want to move. We'll send a scoped statement of work within 5 business days.